Reactions Weekly

, Volume 1175, Issue 1, pp 2–2 | Cite as

Positive benefit-risk balance continues for glitazones – EMEA

News item


Rosiglitazone Pioglitazone Bone Fracture Product Characteristic Ischaemic Heart Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    European Medicines Agency (EMEA).European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Media Release: 18 Oct 2007. Available from: URL:
  2. 2.
    GlaxoSmirthKline.European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment. Media Release: 18 Oct 2007. Available from: URL:

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations